Venus Remedies

Venus Remedies FCF per Share

The Free Cash Flow per Share of Venus Remedies (VENUSREM.NS) as of Nov 10, 2026 is 89.49 INR. In the previous year, Free Cash Flow per Share was 60.81 INR — a change of 47.15% (higher).

FCF per Share

89.49INR

YoY

47.15%

Last updated:

Free Cash Flow per Share of Venus Remedies is 2026 89.49 INR. Free Cash Flow per Share of Venus Remedies was 2025 60.81 INR. It decreases by 47.15% higher compared to the previous year.

The Venus Remedies FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2019
28.70 INR
Jan 1, 2020
56.07 INR
Jan 1, 2021
93.28 INR
Jan 1, 2022
20.42 INR
Jan 1, 2023
21.55 INR
Jan 1, 2024
20.92 INR
Jan 1, 2025
60.81 INR
Jan 1, 2026
89.49 INR
The Venus Remedies FCF per Share history
YEARFCF per ShareYoY
89.49INR+47.15%
60.81INR+190.72%
20.92INR-2.92%
21.55INR+5.53%
20.42INR-78.11%
93.28INR+66.35%
56.07INR+95.34%
28.70INR-5.07%
30.24INR-29.66%
42.99INR-1,703.80%
-2.68INR-1,038.72%
0.29INR-100.84%
-34.04INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Remedies Stock analysis

What does Venus Remedies do? Venus Remedies Ltd. manufactures and trades pharmaceutical products, focusing on injectables, tablets, and topical preparations for therapeutic segments including anti-infective, oncology, skin and wound care, and pain management. The company's brands such as Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful, and Nervolize cater to critical care and super specialty markets. Its product portfolio addresses antimicrobial resistance (AMR), oncology, neurology, anticoagulants, and herbal solutions, serving medicine, surgery, neuro, and orthopedics. The firm operates in the Pharmaceutical Formulation segment with three manufacturing facilities. The company sells its pharmaceutical products to healthcare providers and institutions globally, targeting critical care and super specialty segments. Brands like Potentox and Vancoplus Combi are positioned for antimicrobial resistance (AMR) solutions, while Neurotol and Trois serve neurology and orthopedics. Supime and Zydotum focus on pain management and skin care, and Septiloc and Mucomelt address anticoagulants and wound care. Venus Remedies' formulations include injectables, tablets, and topical preparations for diverse therapeutic needs. Venus Remedies Ltd. generates revenue through the sale of its branded pharmaceutical products, including injectables, tablets, and topical preparations. The company's product lines target specific therapy areas such as AMR, oncology, skin and wound care, and pain management, with brands like Ventaful and Nervolize supporting neurology and anticoagulant markets. The firm's global reach in injectable manufacturing and focus on super specialty segments drive its market positioning within the Pharmaceutical Formulation segment. Venus Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Venus Remedies stock

Free Cash Flow per Share of Venus Remedies is 89.49 INR in 2026.

Free Cash Flow per Share of Venus Remedies changed from 60.81 INR to 89.49 INR, representing a 47.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Venus Remedies since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Venus Remedies

All Key Metrics — Venus Remedies